ReviveMed is an MIT spinout that created the world's most advanced AI platform and a proprietary database with the highest quality and density of metabolite data. While current methods are limited to a few hundred metabolite data points at the most, ReviveMed uses data from 10,000+ metabolites. As a result, in a fraction of the time and cost, we have discovered therapeutic assets for four diseases internally, including NASH and renal cell carcinoma, and in strategic collaboration with big pharma, with a combined therapeutic market value of >$50B.